查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439653

全球鼻腔給藥市場：洞察、競爭格局、市場預測：2030 年

Intranasal Drug Delivery - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

2023年全球鼻腔給藥市場規模將達460億美元。 預計到 2030 年，該市場將達到 663.3 億美元，2024 年至 2030 年的預測期間複合年增長率為 6.29%。 鼻炎和鼻竇炎等各種呼吸系統疾病的全球負擔日益增加，以及鼻腔給藥因其易於給藥和高效而日益受到患者的青睞，推動了鼻腔給藥市場的增長。預計增長將由使用量的增加推動適用於各種病症的鼻內藥物的數量不斷增加，產品核准和上市的數量不斷增加。

由於全球呼吸系統疾病負擔日益加重，鼻腔給藥市場正在顯著成長。

鼻竇炎是一種與鼻腔和鼻竇發炎相關的常見疾病。 根據世界過敏組織報告（2022），慢性鼻竇炎（CRS）的全球盛行率在中國約為8%，韓國為8.4%，歐洲為11%，美國為12%。

此外，根據國際鼻學會 2020 年的報告，急性鼻竇炎（通常由病毒性感冒引起）的 1 年盛行率為 6% 至 15%。CRS 估計會影響 5總人口的-12%。

此外，根據支持患有過敏症的成人和兒童的英國醫療慈善機構 Allergy UK 的數據，據報道，2020 年英國約有 49% 的人患有過敏性鼻炎。

本報告調查了全球鼻腔藥物輸送市場，並按劑型、容器、系統、治療應用、最終用戶、地區和市場進入提供了市場概述。提供公司簡介、 ETC。

目錄

第1章鼻腔給藥市場報告簡介

第2章鼻腔給藥市場執行摘要

第3章監理與專利分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第4章鼻腔給藥市場主要因素分析

  • 推動鼻腔給藥市場的因素
  • 鼻腔給藥市場的限制與挑戰
  • 鼻腔給藥市場機會

第5章鼻腔給藥市場波特五力分析

第6章COVID-19對鼻腔給藥市場的影響分析

第7章鼻腔給藥市場概況

  • 按劑型
  • 按貨櫃
  • 按系統
  • 依治療用途
  • 按最終用戶
  • 按地區

第8章鼻腔給藥全球公司份額分析－3至5家主要公司

第9章鼻腔給藥業者及產品概況

  • AFT Pharmaceuticals
  • AptarGroup, Inc.
  • SaNOtize Research & Development Corp.
  • Becton, Dickinson and Company
  • Oyster Point Pharma, Inc.
  • Impel Neuropharma
  • Teleflex Incorporated
  • SipNose
  • Kurve Technology, Inc.
  • Mystic Pharmaceuticals
  • Medica Holdings, LLC
  • 3M Company
  • Neurelis, Inc.
  • PENDOPHARM
  • GlaxoSmithKline
  • Cipla
  • Glenmark Pharmaceuticals
  • Novartis AG
  • AstraZeneca
  • Johnson & Johnson

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

Product Code: DIMDCL0492

Intranasal Drug Delivery Market By Dosage Form (Spray, Drops And Liquids, Gels, Powders), By Container (Pressurized, Non-Pressurized), By System (Multi-Dose Systems, Bi-Dose Systems, Unit-Dose Systems), By Therapeutic Application (Rhinitis, Sinusitis, Vaccination, Others), By End-User (Hospitals, Home Care Settings), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising burden of various respiratory disorders and extended application of intranasal drugs in various conditions

Global Intranasal Drug Delivery Market was valued at USD 46.00 billion in 2023, growing at a CAGR of 6.29% during the forecast period from 2024 to 2030, in order to reach USD 66.33 billion by 2030. The Intranasal Drug Delivery market is expected to witness growth owing to the rising burden of various respiratory disorders such as rhinitis and sinusitis among the worldwide population, increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy, the extended application of intranasal drugs in various conditions, rise in product approval and launches.

Intranasal Drug Delivery Market Dynamics:

Owing to the growing burden of respiratory diseases across the globe, the Intranasal Drug Delivery market has been rising significantly.

Rhinosinusitis is a common condition associated with the inflammation of the nasal cavity along with paranasal sinuses. According to the World Allergy Organization 2022 report, the worldwide prevalence of chronic rhinosinusitis (CRS) ranges from about 8% in China, 8.4% in Korea, 11% in Europe, and 12% in the United States respectively.

Also, according to the reports of the International Rhinologic Society 2020, the one-year prevalence of acute rhinosinusitis which is usually the consequence of viral common cold is 6-15% whereas CRS affects an estimated 5-12% of the general population.

In addition, according to Allergy UK, a British medical charity dedicated to helping adults and children with their allergies, around 49% of people reported suffering from allergic rhinitis in the UK in the year 2020.

Furthermore, as per the data provided by the Australian Government in the year 2020, approximately 1 in 5 Australians or more than 4.6 million people in Australia had allergic rhinitis in the year 2017-2018.

Report Metrics

Details

Study Period

2021 to 2030

Base Year

2022

Forecast Period

2024 to 2030

CAGR

6.29%

Market Size

USD 66.33 billion by 2030

Key Companies

AFT Pharmaceuticals, AptarGroup, Inc., SaNOtize Research & Development Corp., Becton, Dickinson and Company, Oyster Point Pharma, Inc., Impel Neuropharma, Teleflex Incorporated, SipNose, Kurve Technology, and others

Thus, the rising prevalence of respiratory disorders such as allergic rhinitis, rhinosinusitis, and others are key factors contributing to the Intranasal Drug Delivery market growth during the forecasted period.

COVID-19 has caused significant disruption to business and economic activity globally and is expected to have impacted the intranasal drug delivery market. This is due to factors including lockdown restriction, supply chain disruption due to logistical restrictions, among others. However, the pandemic has also allowed the Intranasal Drug Delivery market as various manufacturers are focused on developing intranasal vaccines for the COVID-19 infection, for instance, Canadian biotech firm SaNOtize Research & Development Corp is one of them.

However, certain factors like complications and limitations associated with the intranasal drug administration and product recalls may restrict the growth of the Global Intranasal Drug Delivery Market.

Intranasal Drug Delivery Market Segment Analysis:

Intranasal Drug Delivery Market By Dosage Form (Spray, Drops and Liquids, Gels, Powders), By Container (Pressurized, Non-Pressurized), By System (Multi-dose Systems, Bi-dose Systems, Unit-dose Systems), By Therapeutic Application (Rhinitis, Sinusitis, Vaccination, Others), By End-User (Hospitals, Home Care Settings), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In Intranasal Drug Delivery market Dosage Form segment, the Sprays market segment will hold the major share of the Global Intranasal Drug Delivery market. This is owing to the wide availability of intranasal sprays to deliver medications locally in the nasal cavities or systemically for various applications such as congested nose, migraine, and others.

Furthermore, rising COVID-19 cases across the globe and an increase in research and development activities for developing intranasal sprays for the infection is also a factor responsible for augmenting the market for intranasal sprays in the forthcoming years.

In addition, the expansion of intranasal spray to treat a variety of different diseases and their approval is also expected to surge the market for intranasal drug delivery in the upcoming years.

Hence, all the above-mentioned factors are expected to bolster the segmental growth in the forthcoming years.

North America is expected to dominate the overall Global Intranasal Drug Delivery Market:

North America is expected to dominate the overall Intranasal Drug Delivery market during the forecast period. This domination is owing to the increasing prevalence of the target population in the region. Moreover, the presence of a well-established reimbursement policy and recent product approvals in the region is projected to augment the intranasal drug delivery regional market.

For instance, as per the 2022 data of the Centre for Disease Control and Prevention, in the US, there are approximately 28.9 million adult persons diagnosed with sinusitis.

Further, in North America and at the global level the United States represents the largest market worldwide supported by developed healthcare infrastructure and strong adoption of technologically advanced products owing to the rise in healthcare expenditure by the government and increase prevalence and incidence of respiratory disease.

In addition, the presence of key market players such as Becton, Dickinson, and Company, Aptar Group., among others, and their strategic business activities for market expansion is also expected to bolster the intranasal drug delivery market in the country.

For instance, on March 18, 2019, Aptar Pharma, a leading drug delivery systems provider received FDA approval for its Bidose nasal spray device as a breakthrough therapy in the field of depression. This marks the first FDA approval and the US launch of a prescription drug using Aptar Pharma's patented Bidose nasal spray delivery system.

Hence, the interplay of all the above-mentioned factors is likely to drive the market for intranasal drug delivery market in the country during the forecasted period.

Intranasal Drug Delivery Market Key Players:

Some of the key market players operating in the Global Intranasal Drug Delivery Market include AFT Pharmaceuticals, AptarGroup, Inc., SaNOtize Research & Development Corp., Becton, Dickinson and Company, Oyster Point Pharma, Inc., Impel Neuropharma, Teleflex Incorporated, SipNose, Kurve Technology, Inc., Mystic Pharmaceuticals, Medica Holdings, LLC, 3M Company, Neurelis, Inc., PENDOPHARM, GlaxoSmithKline, Cipla, Glenmark Pharmaceuticals, Novartis AG, AstraZeneca, Johnson & Johnson, and others.

Recent Developmental Activities in the Intranasal Drug Delivery Market:

In October 2022, Oyster Point Pharma's dry-eye treatment, Tyrvaya (varenicline), won FDA approval as the first nasal spray in the U.S. to treat the chronic condition of dry eye.

On August 02, 2022, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, and Canadian biotech firm SaNOtize Research & Development Corp. inked an exclusive long term strategic partnership to manufacture, market, and distribute its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, and other countries.

Key Takeaways from the Intranasal Drug Delivery Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Intranasal Drug Delivery market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the Global Intranasal Drug Delivery Market.

Various opportunities are available for the other competitor in the Intranasal Drug Delivery Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Intranasal Drug Delivery market growth in the coming future?

Target Audience who can be benefited from this Intranasal Drug Delivery Market Report Study

Intranasal Drug Delivery providers

Research organizations and consulting companies

Intranasal Drug Delivery related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Intranasal Drug Delivery

Various End-users want to know more about the Intranasal Drug Delivery Market and the latest technological developments in the Intranasal Drug Delivery market.

Frequently Asked Questions for Intranasal Drug Delivery Market:

1. What are Intranasal Drug Delivery Devices?

Intranasal drug delivery devices are next-generation post-surgery devices, offering advantages for enhancing tissue recovery through the release of loaded therapeutic drugs locally in a controlled manner over the required time frame during post-operative healing.

2. What is the market for Global Intranasal Drug Delivery?

Global Intranasal Drug Delivery Market was valued at USD 46.00 billion in 2023, growing at a CAGR of 6.29% during the forecast period from 2024 to 2030, in order to reach USD 66.33 billion by 2030.

3. What are the drivers for Global Intranasal Drug Delivery?

The major drivers driving the demand for Intranasal Drug Delivery are the rising burden of various respiratory disorders such as rhinitis and sinusitis among the worldwide population, increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy, the extended application of intranasal drugs in various conditions, rise in product approval and launches.

4. What are the key players operating in Global Intranasal Drug Delivery?

Some of the key market players operating in the Intranasal Drug Delivery market include AFT Pharmaceuticals, AptarGroup, Inc., SaNOtize Research & Development Corp., Becton, Dickinson and Company, Oyster Point Pharma, Inc., Impel Neuropharma, Teleflex Incorporated, SipNose, Kurve Technology, Inc., Mystic Pharmaceuticals, Medica Holdings, LLC, 3M Company, Neurelis, Inc., PENDOPHARM, GlaxoSmithKline, Cipla, Glenmark Pharmaceuticals, Novartis AG, AstraZeneca, Johnson & Johnson, and others.

5. Which regions has the highest share in the Intranasal Drug Delivery market?

North America is expected to dominate the overall global Intranasal Drug Delivery market during the forecast period from 2024 to 2030. This domination is owing to the increasing prevalence of the target population in the region. Moreover, the presence of a well-established reimbursement policy and recent product approvals in the region is projected to augment the intranasal drug delivery regional market.

Table of Contents

1.Intranasal Drug Delivery Market Report Introduction

2.Intranasal Drug Delivery Market Executive summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Intranasal Drug Delivery Market Key factors analysis

  • 4.1 Intranasal Drug Delivery Market Drivers
    • 4.1.1 Rising Burden of various Respiratory Disorders among the Worldwide Population
    • 4.1.2 Increasing Patient Preference for Nasal Drug Delivery
    • 4.1.3 Extended Application of Intranasal Drugs in Various Conditions
    • 4.1.4 The rise in Product Approval and Launches
  • 4.2 Intranasal Drug Delivery Restraints and Challenges
    • 4.2.1 Complications and Limitations associated with the Intranasal Drug Administration
    • 4.2.2 Product Recalls
  • 4.3 Intranasal Drug Delivery Opportunities
    • 4.3.1 Growth Opportunities in Low-Income Regions
    • 4.3.2 Growth Opportunities due to Strategic Business Activities by Companies for Market Expansion

5. Intranasal Drug Delivery Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Intranasal Drug Delivery Market

7. Intranasal Drug Delivery Market layout

  • 7.1 By Dosage Form
    • 7.1.1 Spray
    • 7.1.2 Drops and Liquids
    • 7.1.3 Gels
    • 7.1.4 Powders
  • 7.2 By Container
    • 7.2.1 Pressurized
    • 7.2.2 Non-Pressurized
  • 7.3 By System
    • 7.3.1 Multi-dose Systems
    • 7.3.2 Bi-dose Systems
    • 7.3.3 Unit-dose Systems
  • 7.4 By Therapeutic Application
    • 7.4.1 Rhinitis
    • 7.4.2 Sinusitis
    • 7.4.3 Vaccination
    • 7.4.4 Others
  • 7.5 By End User
    • 7.5.1 Hospitals
    • 7.5.2 Home Care Settings
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 North America Intranasal Drug Delivery Market, by Dosage Form
      • 7.6.1.2 North America Intranasal Drug Delivery Market, by Container
      • 7.6.1.3 North America Intranasal Drug Delivery Market, by System
      • 7.6.1.4 North America Intranasal Drug Delivery Market, by Therapeutic Application
      • 7.6.1.5 North America Intranasal Drug Delivery Market, by End User
      • 7.6.1.6 North America Intranasal Drug Delivery Market, by Country
      • 7.6.1.6.1 United States
      • 7.6.1.6.2 Canada
      • 7.6.1.6.3 Mexico
    • 7.6.2 Europe
      • 7.6.2.1 Europe Intranasal Drug Delivery Market, by Dosage Form
      • 7.6.2.2 Europe Intranasal Drug Delivery Market, by Container
      • 7.6.2.3 Europe Intranasal Drug Delivery Market, by System
      • 7.6.2.4 Europe Intranasal Drug Delivery Market, by Therapeutic Application
      • 7.6.2.5 Europe Intranasal Drug Delivery Market, by End User
      • 7.6.2.6 Europe Intranasal Drug Delivery Market, by Country
      • 7.6.2.6.1 France
      • 7.6.2.6.2 Germany
      • 7.6.2.6.3 United Kingdom
      • 7.6.2.6.4 Italy
      • 7.6.2.6.5 Spain
      • 7.6.2.6.6 Russia
      • 7.6.2.6.7 Rest of Europe
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 Asia-Pacific Intranasal Drug Delivery Market, by Dosage Form
      • 7.6.3.2 Asia-Pacific Intranasal Drug Delivery Market, by Container
      • 7.6.3.3 Asia-Pacific Intranasal Drug Delivery Market, by System
      • 7.6.3.4 Asia-Pacific Intranasal Drug Delivery Market, by Therapeutic Application
      • 7.6.3.5 Asia-Pacific Intranasal Drug Delivery Market, by End User
      • 7.6.3.6 Asia-Pacific Intranasal Drug Delivery Market, by Country
      • 7.6.3.6.1 China
      • 7.6.3.6.2 Japan
      • 7.6.3.6.3 India
      • 7.6.3.6.4 Australia
      • 7.6.3.6.5 South Korea
      • 7.6.3.6.6 Rest of Asia Pacific
    • 7.6.4 Rest of the World (RoW)
      • 7.6.4.1 RoW Intranasal Drug Delivery Market, by Dosage Form
      • 7.6.4.2 RoW Intranasal Drug Delivery Market, by Container
      • 7.6.4.3 RoW Intranasal Drug Delivery Market, by System
      • 7.6.4.4 RoW Intranasal Drug Delivery Market, by Therapeutic Application
      • 7.6.4.5 RoW Intranasal Drug Delivery Market, by End User
      • 7.6.4.6 RoW Intranasal Drug Delivery Market, by Region
      • 7.6.4.6.1 Middle East
      • 7.6.4.6.2 Africa
      • 7.6.4.6.3 South America

8. Intranasal Drug Delivery Global Company Share Analysis - Key 3-5 Companies

9. Intranasal Drug Delivery Company and Product Profiles

  • 9.1 AFT Pharmaceuticals
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 AptarGroup, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 SaNOtize Research & Development Corp.
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Becton, Dickinson and Company
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 Oyster Point Pharma, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Impel Neuropharma
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 Teleflex Incorporated
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 SipNose
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 Kurve Technology, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Mystic Pharmaceuticals
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 Medica Holdings, LLC
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 3M Company
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Neurelis, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 PENDOPHARM
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 GlaxoSmithKline
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 Cipla
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 Glenmark Pharmaceuticals
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 Novartis AG
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 AstraZeneca
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 Johnson & Johnson
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. PROJECT APPROACH

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Intranasal Drug Delivery Market
  • Table 3 Intranasal Drug Delivery Market Analysis in Global (2021-2030)
  • Table 4 Intranasal Drug Delivery Market Analysis in Global by Dosage Form (2021-2030)
  • Table 5 Intranasal Drug Delivery Market Analysis in Global by Container (2021-2030)
  • Table 6 Intranasal Drug Delivery Market Analysis in Global by System (2021-2030)
  • Table 7 Intranasal Drug Delivery Market Analysis in Global by Therapeutic Application (2021-2030)
  • Table 8 Intranasal Drug Delivery Market Analysis in Global by End User (2021-2030)
  • Table 9 Intranasal Drug Delivery Market Analysis in Global by Geography (2021-2030)
  • Table 10 Intranasal Drug Delivery Market Analysis in North America (2021-2030)
  • Table 11 Intranasal Drug Delivery Market Analysis in North America by Dosage Form (2021-2030)
  • Table 12 Intranasal Drug Delivery Market Analysis in North America by Container (2021-2030)
  • Table 13 Intranasal Drug Delivery Market Analysis in North America by System (2021-2030)
  • Table 14 Intranasal Drug Delivery Market Analysis in North America by Therapeutic Application (2021-2030)
  • Table 15 Intranasal Drug Delivery Market Analysis in North America by End User (2021-2030)
  • Table 16 Intranasal Drug Delivery Market Analysis in North America by Country (2021-2030)
  • Table 17 Intranasal Drug Delivery Market Analysis in the US (2021-2030)
  • Table 18 Intranasal Drug Delivery Market Analysis in Canada (2021-2030)
  • Table 19 Intranasal Drug Delivery Market Analysis in Mexico (2021-2030)
  • Table 20 Intranasal Drug Delivery Market Analysis in Europe (2021-2030)
  • Table 21 Intranasal Drug Delivery Market Analysis in Europe by Dosage Form (2021-2030)
  • Table 22 Intranasal Drug Delivery Market Analysis in Europe by Container (2021-2030)
  • Table 23 Intranasal Drug Delivery Market Analysis in Europe by System (2021-2030)
  • Table 24 Intranasal Drug Delivery Market Analysis in Europe by Therapeutic Application (2021-2030)
  • Table 25 Intranasal Drug Delivery Market Analysis in Europe by End User (2021-2030)
  • Table 26 Intranasal Drug Delivery Market Analysis in Europe by Country (2021-2030)
  • Table 27 Intranasal Drug Delivery Market Analysis in France (2021-2030)
  • Table 28 Intranasal Drug Delivery Market Analysis in Germany (2021-2030)
  • Table 29 Intranasal Drug Delivery Market Analysis in UK (2021-2030)
  • Table 30 Intranasal Drug Delivery Market Analysis in Italy (2021-2030)
  • Table 31 Intranasal Drug Delivery Market Analysis in Spain (2021-2030)
  • Table 32 Intranasal Drug Delivery Market Analysis in Russia (2021-2030)
  • Table 33 Intranasal Drug Delivery Market Analysis in Rest of Europe (2021-2030)
  • Table 34 Intranasal Drug Delivery Market Analysis in Asia Pacific (2021-2030)
  • Table 35 Intranasal Drug Delivery Market Analysis in Asia Pacific by Dosage Form (2021-2030)
  • Table 36 Intranasal Drug Delivery Market Analysis in Asia Pacific by Container (2021-2030)
  • Table 37 Intranasal Drug Delivery Market Analysis in Asia Pacific by System (2021-2030)
  • Table 38 Intranasal Drug Delivery Market Analysis in Asia Pacific by Therapeutic Application (2021-2030)
  • Table 39 Intranasal Drug Delivery Market Analysis in Asia Pacific by End User (2021-2030)
  • Table 40 Intranasal Drug Delivery Market Analysis in Asia Pacific by Country (2021-2030)
  • Table 41 Intranasal Drug Delivery Market Analysis in China (2021-2030)
  • Table 42 Intranasal Drug Delivery Market Analysis in Japan (2021-2030)
  • Table 43 Intranasal Drug Delivery Market Analysis in India (2021-2030)
  • Table 44 Intranasal Drug Delivery Market Analysis in Australia (2021-2030)
  • Table 45 Intranasal Drug Delivery Market Analysis in South Korea (2021-2030)
  • Table 46 Intranasal Drug Delivery Market Analysis in Rest of Asia Pacific (2021-2030)
  • Table 47 Intranasal Drug Delivery Market Analysis in Rest of the World (2021-2030)
  • Table 48 Intranasal Drug Delivery Market Analysis in Rest of the World by Dosage Form (2021-2030)
  • Table 49 Intranasal Drug Delivery Market Analysis in Rest of the World by Container (2021-2030)
  • Table 50 Intranasal Drug Delivery Market Analysis in Rest of the World by System (2021-2030)
  • Table 51 Intranasal Drug Delivery Market Analysis in Rest of the World by Therapeutic Application (2021-2030)
  • Table 52 Intranasal Drug Delivery Market Analysis in Rest of the World by End User (2021-2030)
  • Table 53 Intranasal Drug Delivery Market Analysis in Rest of the World by Country (2021-2030)
  • Table 54 Intranasal Drug Delivery Market Analysis in Middle East (2021-2030)
  • Table 55 Intranasal Drug Delivery Market Analysis in Africa (2021-2030)
  • Table 56 Intranasal Drug Delivery Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Intranasal Drug Delivery Market
  • Figure 3 Intranasal Drug Delivery Market Analysis in Global (2021-2030)
  • Figure 4 Intranasal Drug Delivery Market Analysis in Global by Dosage Form (2021-2030)
  • Figure 5 Intranasal Drug Delivery Market Analysis in Global by Container (2021-2030)
  • Figure 6 Intranasal Drug Delivery Market Analysis in Global by System (2021-2030)
  • Figure 7 Intranasal Drug Delivery Market Analysis in Global by Therapeutic Application (2021-2030)
  • Figure 8 Intranasal Drug Delivery Market Analysis in Global by End User (2021-2030)
  • Figure 9 Intranasal Drug Delivery Market Analysis in Global by Geography (2021-2030)
  • Figure 10 Intranasal Drug Delivery Market Analysis in North America (2021-2030)
  • Figure 11 Intranasal Drug Delivery Market Analysis in North America by Dosage Form (2021-2030)
  • Figure 12 Intranasal Drug Delivery Market Analysis in North America by Container (2021-2030)
  • Figure 13 Intranasal Drug Delivery Market Analysis in North America by System (2021-2030)
  • Figure 14 Intranasal Drug Delivery Market Analysis in North America by Therapeutic Application (2021-2030)
  • Figure 15 Intranasal Drug Delivery Market Analysis in North America by End User (2021-2030)
  • Figure 16 Intranasal Drug Delivery Market Analysis in North America by Country (2021-2030)
  • Figure 17 Intranasal Drug Delivery Market Analysis in the US (2021-2030)
  • Figure 18 Intranasal Drug Delivery Market Analysis in Canada (2021-2030)
  • Figure 19 Intranasal Drug Delivery Market Analysis in Mexico (2021-2030)
  • Figure 20 Intranasal Drug Delivery Market Analysis in Europe (2021-2030)
  • Figure 21 Intranasal Drug Delivery Market Analysis in Europe by Dosage Form (2021-2030)
  • Figure 22 Intranasal Drug Delivery Market Analysis in Europe by Container (2021-2030)
  • Figure 23 Intranasal Drug Delivery Market Analysis in Europe by System (2021-2030)
  • Figure 24 Intranasal Drug Delivery Market Analysis in Europe by Therapeutic Application (2021-2030)
  • Figure 25 Intranasal Drug Delivery Market Analysis in Europe by End User (2021-2030)
  • Figure 26 Intranasal Drug Delivery Market Analysis in Europe by Country (2021-2030)
  • Figure 27 Intranasal Drug Delivery Market Analysis in France (2021-2030)
  • Figure 28 Intranasal Drug Delivery Market Analysis in Germany (2021-2030)
  • Figure 29 Intranasal Drug Delivery Market Analysis in UK (2021-2030)
  • Figure 30 Intranasal Drug Delivery Market Analysis in Italy (2021-2030)
  • Figure 31 Intranasal Drug Delivery Market Analysis in Spain (2021-2030)
  • Figure 32 Intranasal Drug Delivery Market Analysis in Russia (2021-2030)
  • Figure 33 Intranasal Drug Delivery Market Analysis in Rest of Europe (2021-2030)
  • Figure 34 Intranasal Drug Delivery Market Analysis in Asia Pacific (2021-2030)
  • Figure 35 Intranasal Drug Delivery Market Analysis in Asia Pacific by Dosage Form (2021-2030)
  • Figure 36 Intranasal Drug Delivery Market Analysis in Asia Pacific by Container (2021-2030)
  • Figure 37 Intranasal Drug Delivery Market Analysis in Asia Pacific by System (2021-2030)
  • Figure 38 Intranasal Drug Delivery Market Analysis in Asia Pacific by Therapeutic Application (2021-2030)
  • Figure 39 Intranasal Drug Delivery Market Analysis in Asia Pacific by End User (2021-2030)
  • Figure 40 Intranasal Drug Delivery Market Analysis in Asia Pacific by Country (2021-2030)
  • Figure 41 Intranasal Drug Delivery Market Analysis in China (2021-2030)
  • Figure 42 Intranasal Drug Delivery Market Analysis in Japan (2021-2030)
  • Figure 43 Intranasal Drug Delivery Market Analysis in India (2021-2030)
  • Figure 44 Intranasal Drug Delivery Market Analysis in Australia (2021-2030)
  • Figure 45 Intranasal Drug Delivery Market Analysis in South Korea (2021-2030)
  • Figure 46 Intranasal Drug Delivery Market Analysis in Rest of Asia Pacific (2021-2030)
  • Figure 47 Intranasal Drug Delivery Market Analysis in Rest of the World (2021-2030)
  • Figure 48 Intranasal Drug Delivery Market Analysis in Rest of the World by Dosage Form (2021-2030)
  • Figure 49 Intranasal Drug Delivery Market Analysis in Rest of the World by Container (2021-2030)
  • Figure 50 Intranasal Drug Delivery Market Analysis in Rest of the World by System (2021-2030)
  • Figure 51 Intranasal Drug Delivery Market Analysis in Rest of the World by Therapeutic Application (2021-2030)
  • Figure 52 Intranasal Drug Delivery Market Analysis in Rest of the World by End User (2021-2030)
  • Figure 53 Intranasal Drug Delivery Market Analysis in Rest of the World by Country (2021-2030)
  • Figure 54 Intranasal Drug Delivery Market Analysis in Middle East (2021-2030)
  • Figure 55 Intranasal Drug Delivery Market Analysis in Africa (2021-2030)
  • Figure 56 Intranasal Drug Delivery Market Analysis in South America (2021-2030)
  • Figure 57 Market Drivers
  • Figure 58 Market Barriers
  • Figure 59 Market Opportunities
  • Figure 60 PORTER'S Five Force Analysis